Capricor Therapeutics AI Stock Analysis
Want to see CAPR full AI Analyst Report?
Capricor Therapeutics (CAPR) AI Stock Analysis
Capricor Therapeutics
(NASDAQ:CAPR)
CAPR’s score is held back primarily by weak financial performance (no current revenue, large and worsening losses, and significant cash burn). Offsetting this are a constructive technical setup and a relatively positive earnings-call backdrop driven by HOPE-3 efficacy/safety updates and active launch preparation, though the pending FDA decision and rising expenses remain key risks.
Capricor Therapeutics (CAPR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $487.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.69M
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- 1.93
- Revenue Growth
- -100.00%
- EPS Growth
- -47.08%
- Country
- US
- Employees
- 231
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Capricor Therapeutics Business Overview & Revenue Model
Company Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which re...
How the Company Makes Money
As a clinical-stage biotechnology company, Capricor has historically generated little to no recurring revenue from product sales because its lead candidates have been in development and not broadly commercialized. When revenue is present, it is typic...
Capricor Therapeutics Earnings Call Summary
The call was predominantly positive, supported by a statistically significant HOPE-3 primary endpoint, favorable two-year extension and integrated-trial data, positive safety experience, cardiac-data recognition, FDA review progress, launch preparation, manufacturing readiness, and a cash runway of at least 12 months. Key negatives were the still-pending FDA decision, the ongoing NS Pharma dispute, no recognized revenue, higher operating expenses, larger net losses, a nonsignificant overall ejection-fraction result, and a 10% workforce reduction. The highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said the FDA review remains ongoing with the PDUFA target action date extended to November 22, 2026, after submission of an amendment containing approximately 30,000 pages, and the proposed refined indication is for patients with age greater than 9 years old; commercial readiness is underway across distribution, patient support, market access, medical affairs, and physician education, while the San Diego GMP facility is ready for an initial launch, with the first-floor clean room able to meet the needs of 250 patients per year or around 1000 doses per year and the second floor expected to support 2,000 to 2500 patients or up to 10,000 doses per year operating at full capacity, with validation targeted for the first half of 2020; the company estimates approximately 15,000 people in The US are living with DMD, roughly 2-thirds are ages 9 and older, expects arbitration to commence in mid-2027, reduced its workforce by approximately 10% in the third quarter, reported approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, and believes its existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months.
Capricor Therapeutics Financial Statement Overview
Summary
Financials are weak overall: revenue is inconsistent and falls to zero in 2025 annual and TTM, losses are large and worsening (TTM EBIT -$153.6M; TTM net loss -$147.5M), and cash burn is heavy with deeply negative free cash flow (TTM -$146.3M). The balance sheet provides some cushion via meaningful equity, but rising leverage in TTM increases risk if burn persists.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 22.27M | 25.18M | 2.55M | 244.90K |
| Gross Profit | 0 | 0 | -27.70M | -11.27M | -19.27M | 244.90K |
| EBITDA | 1.16B | -100.11M | -39.04M | -21.22M | -28.49M | -19.78M |
| Net Income | -147.50M | -105.04M | -40.47M | -22.29M | -29.02M | -20.02M |
Balance Sheet | ||||||
| Total Assets | 330.37M | 355.95M | 170.48M | 58.73M | 50.09M | 41.33M |
| Cash, Cash Equivalents and Short-Term Investments | 197.58M | 318.13M | 151.52M | 39.49M | 41.42M | 34.89M |
| Total Debt | 92.23M | 17.94M | 4.83M | 5.61M | 5.94M | 6.25M |
| Total Liabilities | 120.61M | 50.16M | 25.02M | 36.13M | 38.31M | 9.96M |
| Stockholders Equity | 209.76M | 305.79M | 145.46M | 22.60M | 11.79M | 31.37M |
Cash Flow | ||||||
| Free Cash Flow | -146.29M | -72.72M | -41.53M | -27.64M | 1.56M | -18.01M |
| Operating Cash Flow | -119.99M | -69.81M | -40.00M | -25.60M | 4.92M | -16.81M |
| Investing Cash Flow | -100.41M | 97.48M | -116.18M | 5.11M | -35.07M | -1.20M |
| Financing Cash Flow | 246.13M | 248.89M | 152.77M | 25.58M | 4.87M | 20.23M |
Capricor Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Negative. The current price of 8.41 is above the 20-day moving average (MA) of 7.87, above the 50-day MA of 8.07, and below the 200-day MA of 19.81, indicating a neutral trend. The MACD of 0.47 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 26.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPR.
Capricor Therapeutics Risk Analysis
Capricor Therapeutics disclosed 32 risk factors in its most recent earnings report. Capricor Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCapricor Therapeutics Peers Comparison
Overall Rating
CAPR55Neutral
RGNX51Neutral
ABEO47Neutral
SLDB44Neutral
LXEO43Neutral
RCKT42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $488.98M | -3.26 | -56.71% | ― | -100.00% | -47.08% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $478.73M | -2.23 | -203.98% | ― | -4.59% | 8.03% | |
| 47Neutral | $148.58M | -2.30 | -44.82% | ― | 9652.75% | -172.49% | |
| 44Neutral | $695.33M | -3.49 | -67.78% | ― | ― | 28.59% | |
| 43Neutral | $236.36M | -2.33 | -45.29% | ― | ― | 53.48% | |
| 42Neutral | $235.60M | -15.11 | -5.34% | ― | ― | 93.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CAPR | Capricor Therapeutics, Inc. | 8.41 | 2.64 | 45.75% | |
| RCKT | Rocket Pharma | 2.11 | -0.77 | -26.74% | |
| ABEO | Abeona Therapeutics Inc | 2.60 | -1.60 | -38.10% | |
| RGNX | RegenXBio Inc. | 7.24 | -3.69 | -33.76% | |
| SLDB | Solid Biosciences | 6.23 | 1.75 | 39.06% | |
| LXEO | Lexeo Therapeutics, Inc. | 2.85 | -6.23 | -68.59% |
Capricor Therapeutics Corporate Events
Capricor Therapeutics Faces FDA Delay for Deramiocel Review
NegativeOn August 24, 2026, Capricor Therapeutics announced that the U.S. Food and Drug Administration extended the Prescription Drug User Fee Act target action date for its Biologics License Application for Deramiocel, an investigational cell therapy for Du...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
